A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2017
At a glance
- Drugs ADVAX (Primary) ; Influenza A virus H5N1 vaccines (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- Sponsors Vaxine
- 20 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2018.
- 20 Nov 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
- 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.